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cause of mortality. Recent reports have described increasing incidence of invasive non-Asper-
gillus mold infections in patients with hematological malignancies. It is always challenging to
treat invasive fungal infection and underlying hematological malignancies successfully. Here
we report a girl with high-risk acute lymphoblastic leukemia who developed disseminated Cun-
ninghamella bertholletiae infection during induction chemotherapy. This case illustrates the
difficulties of diagnosis and treatment of invasive C. bertholletiae infection. It also highlights
the necessity for physicians to keep high suspicion and awareness for this infrequent fungal
infection.
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532 Y.-Y. Su et al1. Introduction
Invasive fungal infections are serious and often fatal
complications in immunocompromised patients, especially
those with hematological malignancy. The diagnosis and
antifungal treatment among these patients are often
delayed because of a lack of specific clinical and radio-
logical features. The incidence of invasive fungal in-
fections in children with cancer is around 4.9e7.2%, and
the mortality is about 21.7e59%.1e3 Cunninghamella ber-
tholletiae is a rarely reported species of invasive fungal
infection and the lung is the most commonly involved
organ. In pediatric patients, it causes rapid progression
and therefore a high mortality rate. Here we present a
patient with Philadelphia chromosome positive (Phþ)
acute lymphoblastic leukemia (ALL) who developed inva-
sive C. bertholletiae infection during induction chemo-
therapy. This case illustrates the difficulties of diagnosis
and treatment of invasive C. bertholletiae infection. It
also highlights the necessity for physicians to keep high
suspicion and awareness for this infrequent fungal
infection.Figure 1 (A) Computed tomography (CT) scan of the chest show
the left upper lobe. (B) CT scan of the abdomen shows a low-dens
the spleen (arrow). (C) Magnetic resonance imaging of the brain,
enhancement at the right frontal lobe (arrow). (D) CT scan of the
posterior muscle group of left thigh (arrow).2. Case report
A 13-year-old girl presented with hyperleukocytosis
(leukocyte count 135.8  109 cells/L with 91% blasts) and
was diagnosed as Phþ ALL in October 2010. She received
chemotherapy according to the Taiwan Pediatric Oncology
Group (TPOG) 2002-ALL-VHR protocol.4 The leukocyte
count was < 1  109 cells/L on Day 8. Antifungal prophy-
laxis with fluconazole was used from then onwards. She also
received routine Pneumocystis jiroveci pneumonia pro-
phylaxis with cotrimoxazole according to the TPOG
protocol.
She developed cough, occasional hemoptysis, and dys-
pnea on Day 23. Chest radiography revealed a nodule over
the left upper lobe. She was started on voriconazole.
Computed tomography (CT) of chest and abdomen showed
mixed nodularity and groundglass appearance (halo sign) at
left upper lobe (Figure 1A), and a hypodense lesion at the
spleen with adjacent soft tissue edema (Figure 1B). These
findings were suggestive of invasive fungal infection,
particularly invasive aspergillosis. Chemotherapy was dis-
continued and a granulocyte-stimulating factor was given.s a mixed nodularity and groundglass appearance (halo sign) at
ity nodular lesion with inconspicuous contrast enhancement at
T1 weighted image, shows a nodular lesion with partial rim
legs shows a low-density mass with rim enhancement at the
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left lung as well as massive pleural effusion in 1 week. She
also had progressive incoherent speech and tremor. Mag-
netic resonance imaging of brain showed a small round
lesion with post contrast ring enhancement suggestive of
brain abscess (Figure 1C). Serum galactomannan test was
negative. Her general condition improved gradually after
the leukocyte count was elevated. Consolidation and
pleural effusion at the left lung was persistent in the series
of chest radiographs. The bone marrow examination after
incomplete induction chemotherapy showed ALL in
morphological remission. Further intensive chemotherapy
was withheld, and she took imatinib for treatment of Phþ
ALL.
About 6 weeks later, a follow-up CT scan of the whole
body showed necrotizing pneumonia with empyema at the
left upper lung. In addition to the stationary splenic lesion
and brain abscess, abscess at the left thigh was found
(Figure 1D). The patient underwent surgical intervention
with decortication and wedge resection of the lung. The
histology examination revealed extensive necrosis with a
small focal area of invasive fungal disease. Microbiologic
examinations showed broad and nonseptated hyphae, sug-
gesting mucormycosis rather than aspergillosis (Figure 2).
The fungal culture was negative. In order to elucidate the
causative organism, we extracted the DNA from the lung
biopsy specimen and amplified the sequences by polymer-
ase chain reaction. The amplified sequences matched C.
bertholletiae to 95%. Voriconazole was immediately
substituted by amphotericin-B deoxycholate (AmB). Un-
fortunately, a frank relapse of ALL occurred soon after C.
bertholletiae infection was diagnosed. She received re-
induction chemotherapy concomitantly with AmB. She
developed pancytopenia and septic shock 2 weeks after re-
induction chemotherapy. She was transferred to the pedi-
atric intensive care unit. Disseminated intravascular coa-
gulopathy occurred and resulted in massive gastrointestinal
bleeding and multifocal intracranial hemorrhages. Owing to
the poor prognosis, the decision to withdraw life-sustaining
treatment was made in close discussion with her parents.
She died on the following day.Figure 2 Broad and aseptated fungal hyphae in the lung
parenchyma.3. Discussion
The incidence of mucormycete (formerly zygomycetes) in-
fections in immunocompromised patients has been
increasing during the past 2 decades. The annual incidence
of mucormycosis increased with age from 0.3/million in
children aged 0e9 years to 3.9/million in patients aged
> 89 years.5 The most common types of infection were
sinus (39%), pulmonary (24%), and cutaneous (19%).
Dissemination developed in 23% of cases.6 Various envi-
ronmental factors such as use of more potent immunosup-
pressive therapy and some antifungal agents probably
account for the increasing incidence. Rhizopus is the most
common genus causing human mucormycetes infections,
followed by genera such as Mucor and Lichtheimia, ac-
counting for 70e80% of all mucormycosis cases. By
contrast, Cunninghamella, Apophysomyces, Saksenaea,
Rhizomucor, Cokeromyces, Actinomucor, and Syncephalas-
trum species are individually responsible for < 1e5% of
reported cases of mucormycosis.7 The diagnosis of mucor-
mycosis is difficult. Despite the availability of modern
methods (e.g., tissue polymerase chain reaction), about
10% of patients were diagnosed post mortem or during the
last 24 hours prior to death.8 The mortality rate is usually
high (around 50%).8
Among the major mucormycete species, C. bertholle-
tiae is especially difficult to treat, and the overall mortality
rate is up to 77%.7 In an animal study, C. bertholletiae
infection demonstrated greater virulence (higher spor-
angiospore germination rate and hyphal metabolic activity)
than other mucormycete species.9 C. bertholletiae also
exhibited increased resistance to human neutrophils-
induced hyphal damage and is more capable of suppress-
ing release of IL-8 as compared to other mucormycete
species.10 To our knowledge, only 12 children with C. ber-
tholletiae infection have been reported, four of whom
(33%) had disseminated infection. Only one child with
disseminated infection survived.11
It is not easy to distinguishmucormycosis and aspergillosis
clinically as illustrated in our patient. The pathophysiology,
mode of acquisition, and underlying patient risk factors are
similar between the two entities. Predictors of mucormy-
cosis in patients with cancer including concomitant sinusitis,
voriconazole prophylaxis, the presence of multiple ( 10)
nodules and pleural effusion at the time of CT have been
proposed.12 Other clues such as chest wall cellulitis adjacent
to the pulmonary lesion, reverse halo sign in chest radiog-
raphy or CT, and presumed (by CTfindings) fungal pneumonia
with repetitively negative galactomannan levels may also
prompt a high index of suspicion for mucormycosis.13 In our
patient,mixed nodularity and halo sign at the left upper lobe
led us to speculate invasive aspergillosis. However, a nega-
tive galactomannan test, inferior response to voriconazole,
and the extent of dissemination suggested the diagnosis of
mucormycosis. Although proven mucormycosis was diag-
nosed in our patient, the fungus culture was unable to yield
any organism. In this setting, molecular techniques can help
precisely identify the fungal species in a timely manner.
Therefore, we suggest molecular diagnosis should be imple-
mented with conventional histopathological examination if
possible.
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mucormycosis therapy for decades. On the grounds of lower
nephrotoxicity and the greater degree of safety at higher
doses for a longer period of treatment, the lipid formula-
tions of AmB are generally preferred. Posaconazole has
demonstrated utility as salvage therapy for mucormy-
cosis.14,15 Posaconazole may also be used as first-line
therapy in patients with the presence or a reasonable
expectation of renal dysfunction. In a retrospective case
series, combination polyene plus caspofungin therapy was
associated with significantly improved survival for patients
with rhino-orbitocerebral mucormycosis compared with
polyene monotherapy.16 Further study is warranted to
determine whether polyene-echinocandin is indeed supe-
rior to polyene monotherapy.
In conclusion, we report a child with Phþ ALL who
developed disseminated Cunninghamella bertholletiae
infection during induction chemotherapy. We demon-
strated the difficulties with invasive fungal infection in
children with hematological malignancies. Our report
highlights the necessity for physicians to keep high suspi-
cion and awareness for this infrequent fungal infection in
children with cancer.
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